Chronic obstructive pulmonary diseases in children

Duijts, 2014, Early origins of chronic obstructive lung diseases across the life course, Eur J Epidemiol., 29, 871, 10.1007/s10654-014-9981-5 Braman, 2015, The chronic obstructive pulmonary disease – asthma overlap syndrome, Allergy Asthma Proc., 36, 112, 10.2500/aap.2015.36.3802 Bousquet, 2014, Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies, Curr. Pharm. Des., 20, 1, 10.2174/1381612820666140314115505 Chang, 2015, Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines, Med J Aust., 202, 21, 10.5694/mjac14.00287 Chmiel, 2002, The role of inflammation in the pathophysiology of CF lung disease, Clin Rev Allergy Immunol., 23, 5, 10.1385/CRIAI:23:1:005 Bacharier, 2008, Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report, Allergy., 63, 5, 10.1111/j.1398-9995.2007.01586.x Edmond, 2012, Long term sequelae from childhood pneumonia; systematic review and meta analysis, PLoS ONE, 7, e31239, 10.1371/journal.pone.0031239 Chan, 2015, Pneumonia in childhood and impaired lung function in adults: a longitudinal study, Pediatrics., 135, 607, 10.1542/peds.2014-3060 Ronkainen, 2015, New BPD predicts lung function at school age: Follow‐up study and meta‐analysis, Pediatr Pulmonol., 50, 1090, 10.1002/ppul.23153 Spagnolo, 2013, Long‐term macrolide treatment for chronic respiratory disease, Eur Respir J., 42, 239, 10.1183/09031936.00136712 Parnham, 2014, Azithromycin: mechanisms of action and their relevance for clinical applications, Pharmacol Ther., 143, 225, 10.1016/j.pharmthera.2014.03.003 Brusselle, 2014, Is there a role for macrolides in severe asthma, Curr Opin Pulm Med., 20, 95, 10.1097/MCP.0000000000000017 Simpson, 2009, Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis, Pharmacol Ther., 124, 86, 10.1016/j.pharmthera.2009.06.004 Brusselle, 2013, Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double‐blind placebo‐controlled trial, Thorax., 68, 322, 10.1136/thoraxjnl-2012-202698 Bousquet, 2014, International European Respiratory Society/American Thoracic Society guidelines on severe asthma, Eur Respir J., 44, 1377, 10.1183/09031936.00102714 Global Strategy for Asthma Management and Prevention. [citado em 26 de março de 2015]. Disponível em: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes da Sociedade Brasileira de Pneumologia e Tisiologia para o manejo da asma. J Bras Pneumol. 2012;38:S1‐46. British Thoracic Society ‐ Scottish Intercollegiate Guidelines Network ‐ British guideline on the management of asthma ‐ A national clinical guideline. Revised 2014. [citado em 16 de março de 2015]. Disponível em: www.brit‐thoracic.org.uk. British guideline on the management of asthma. British Thoracic Society; Scottish Intercollegiate Guidelines Network. Thorax. 2014;69:S1‐192. Diagnosis and management of asthma in children 5 years and younger. A guide for health care professionals. Revised 2014. [citado em 28 de março de 2015]. Disponível em: http://www.ginasthma.org/local/uploads/files/GINA_Pediatric_Pocket_2014.pdf. Clinical guidelines for the care of children with cystic fibrosis 2014 ‐ Royal Brompton Hospital. 2014 6th edition. [citado em 28 de março de 2015]. Disponível em: www.rbht.nhs.uk/childrencf. Flume, 2009, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations, Am J Respir Crit Care Med., 180, 802, 10.1164/rccm.200812-1845PP Rabin, 2004, Pulmonary exacerbations in cystic fibrosis, Pediatr Pulmonol., 37, 400, 10.1002/ppul.20023 Werner, 2015, Diagnosis and management of primary ciliary dyskinesia, Cilia., 4, 2, 10.1186/s13630-014-0011-8 Barbato, 2009, Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children, Eur Respir J., 34, 1264, 10.1183/09031936.00176608 Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Front Pharmacol. 2015;16;6:12. Champs, 2011, Post‐infectious bronchiolitis obliterans in children, J Pediatr (RioJ)., 87, 187 James, 2010, Changes in the prevalence of asthma in adults since 1966: the Busselton health study, Eur Respir J., 35, 273, 10.1183/09031936.00194308 Martinez, 2009, The origins of asthma and chronic obstructive pulmonary disease in early life, Proc Am Thorac Soc., 6, 272, 10.1513/pats.200808-092RM Edmond, 2012, Long term sequelae from childhood pneumonia; systematic review and metaanalysis, PLoS ONE., 7, e31239, 10.1371/journal.pone.0031239 Guilbert, 2010, Role of infection in the development and exacerbation of asthma, Expert Rev Respir Med., 4, 71, 10.1586/ers.09.60 Chipps, 2011, Phenotypic expressions of childhood wheezing and asthma: implications for therapy, J Pediatrics., 158, 878, 10.1016/j.jpeds.2011.01.057 Just, 2015, What lessons can be learned about asthma phenotypes in children from cohort studies?, Pediatr Allergy Immunol., 26, 300, 10.1111/pai.12359 He, 2011, Inflammatory phenotypes in stable and acute childhood asthma, Paediatr Respir Rev., 12, 165, 10.1016/j.prrv.2011.04.007 Saglani, 2006, Investigation of young children with severe recurrent wheeze: any clinical benefit, Eur Respir J., 27, 29, 10.1183/09031936.06.00030605 Fogaça, 2014, Epidemiological aspects of and risk factors for wheezing in the first year of life, J Bras Pneumol., 40, 617, 10.1590/S1806-37132014000600005 Mallol, 2010, International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources, Thorax., 65, 1004, 10.1136/thx.2009.115188 Guilbert, 2004, Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma, J Allergy Clin Immunol., 114, 6, 10.1016/j.jaci.2004.09.020 Stapleton, 2011, Smoking and Asthma, Review J Am Board Fam Med., 24, 313, 10.3122/jabfm.2011.03.100180 Stocks, 2003, The effect of parental smoking on lung function and development during infancy, Respirology., 8, 266, 10.1046/j.1440-1843.2003.00478.x Oberg, 2011, Worldwide burden of disease from exposure to second‐hand smoke: a retrospective analysis of data from 192 countries, Lancet., 377, 139, 10.1016/S0140-6736(10)61388-8 Busse, 2010, Role of viral respiratory infections in asthma and asthma exacerbations, Lancet., 376, 826, 10.1016/S0140-6736(10)61380-3 Martinez, 1995, Asthma and wheezing in the first six years of life, N Engl J Med., 332, 133, 10.1056/NEJM199501193320301 Castro-Rodriguez, 2000, A clinical index to define risk of asthma in young children with recurrent wheezing, Am J Respir Crit Care Med., 162, 1403, 10.1164/ajrccm.162.4.9912111 Fouzas, 2013, Predicting persistence of asthma in preschool wheezers: crystal balls or muddy waters?, Paediatr Respir Rev., 14, 46, 10.1016/j.prrv.2012.08.004 Brand, 2010, The asthma predictive index: not a useful tool in clinical practice, J Allergy Clin Immunol., 127, 293, 10.1016/j.jaci.2010.10.012 Huffaker, 2014, Utility of the Asthma Predictive Index in predicting childhood asthma and identifying disease‐modifying interventions, Ann Allergy Asthma Immunol., 112, 188, 10.1016/j.anai.2013.12.001 Castro-Rodriguez, 2013, The necessity of having asthma predictive scores in children, J Allergy Clin Immunol., 132, 1311, 10.1016/j.jaci.2013.09.006 Guilbert, 2006, Long‐term inhaled corticosteroids in preschool children at high risk for asthma, New Eng J Med., 354, 1985, 10.1056/NEJMoa051378 Castro-Rodriguez, 2009, Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta‐analysis, Pediatrics., 123, e519, 10.1542/peds.2008-2867 Castro-Rodriguez, 2013, Efficacy of inhaled corticosteroids in wheezy infants/preschoolers, Respir Med., 107, 153, 10.1016/j.rmed.2012.10.010 Colom, 2006, Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis, Thorax, 61, 503, 10.1136/thx.2005.044909 Castro-Rodriguez, 2006, Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5‐year follow‐up, Pediatr Pulmonol., 41, 947, 10.1002/ppul.20472 Colom, 2015, Pulmonary function of a paediatric cohort of patients with post infectious bronchiolitis obliterans, A long term follow‐up. Thorax, 70, 169 Rosewich, 2015, Airway inflammation in children and adolescents with bronchiolitis obliterans, Cytokine., 73, 156, 10.1016/j.cyto.2014.10.026 Colom, 2009, Clinical prediction rule to diagnose post‐infectious bronchiolitis obliterans in children, Pediatr Pulmonol, 44, 1065, 10.1002/ppul.21080 Mauad, 2002, Histology of Childhood Bronchiolitis Obliterans, Pediatr Pulmonol., 33, 466, 10.1002/ppul.10097 Myers, 1993, Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia and diffuse panbronchiolitis, Clin Chest Med., 14, 611, 10.1016/S0272-5231(21)00925-4 Zhang, 1999, High‐resolution computed tomography in pediatric patients with postinfectious bronchiolitis obliterans, J Thorac Imaging., 14, 85, 10.1097/00005382-199904000-00003 Fischer, 2010, Post infectious bronchiolitis obliterans in children, Paediatr Respir Rev., 11, 233, 10.1016/j.prrv.2010.07.005 Vega-Briceno, 2009, Clinical guide for diagnosis and care of children and adolescents with post‐infectious bronchiolitis obliterans, Rev Chil Enf Resp., 25, 141 Mattiello, 2010, Pulmonary function in children and adolescents with postinfectious bronchiolitis obliterans, J Bras Pneumol., 36, 453, 10.1590/S1806-37132010000400010 Noone, 2004, Primary ciliary dyskinesia: diagnostic and phenotypic features, Am J Respir Crit Care Med., 169, 459, 10.1164/rccm.200303-365OC O’Callaghan, 2010, High prevalence of primary ciliary dyskinesia in a British Asian population, Arch Dis Child., 95, 51, 10.1136/adc.2009.158493 Knowles, 2013, Primary ciliary dyskinesia: recent advances in diagnostics, genetics, and characterization of clinical disease, Am J Respir Crit Care Med., 188, 913, 10.1164/rccm.201301-0059CI Hosie, 2015, Presentation of primary ciliary dyskinesia in children: 30 years’ experience, J Paediatr Child Health., 51, 722, 10.1111/jpc.12791 Brown, 2008, Early lung disease in young children with primary ciliary dyskinesia, Pediatr Pulmonol., 43, 514, 10.1002/ppul.20792 Horani, 2014, Picking up speed: advances in the genetics of primary ciliary dyskinesia, Pediatr Res., 75, 158, 10.1038/pr.2013.200 Leigh, 2013, Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia, Ann Am Thorac Soc., 10, 574, 10.1513/AnnalsATS.201305-110OC Stoltz, 2015, Origins of cystic fibrosis lung disease, N Engl J Med., 372, 351, 10.1056/NEJMra1300109 Goss, 2015, Children and young adults with CF in the USA have better lung function compared with the UK, Thorax., 70, 229, 10.1136/thoraxjnl-2014-205718 Marson, 2015, Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis, BMC Pulm Med., 15, 3, 10.1186/1471-2466-15-3 Hoo, 2012, Lung function is abnormal in 3‐month‐old infants with cystic fibrosis diagnosed by newborn screening, Thorax., 67, 874, 10.1136/thoraxjnl-2012-201747 Sly, 2013, Risk factors for bronchiectasis in children with cystic fibrosis, N Engl J Med., 368, 1963, 10.1056/NEJMoa1301725 Meyerholz, 2010, Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children, Am J Respir Crit Care Med., 182, 1251, 10.1164/rccm.201004-0643OC Regamey, 2011, Airway remodelling and its relationship to inflammation in cystic fibrosis, Thorax., 66, 624, 10.1136/thx.2009.134106 Peterson-Carmichael, 2009, Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis, Pediatr Pulmonol., 44, 503, 10.1002/ppul.21044 Servidoni, 2013, Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility, BMC Gastroenterology., 13, 91, 10.1186/1471-230X-13-91 Sousa, 2012, Measurements of CFTR‐mediated Cl‐ secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis, PLoS One., 7, e47708, 10.1371/journal.pone.0047708 Ooi, 2014, Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single‐organ manifestations of cystic fibrosis, Thorax., 69, 254, 10.1136/thoraxjnl-2013-203832 Eakin, 2013, The impact of medication adherence on lung health outcomes in cystic fibrosis, Curr Opin Pulm Med., 19, 687, 10.1097/MCP.0b013e3283659f45 Chmiel, 2014, Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi, Ann Am Thorac Soc., 11, 1298, 10.1513/AnnalsATS.201405-203AS Chmiel, 2014, Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin‐resistant Staphylococcus aureus, gram‐negative bacteria, and multiple infections, Ann Am Thorac Soc., 11, 1120, 10.1513/AnnalsATS.201402-050AS Flume, 2007, CF pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med., 176, 957, 10.1164/rccm.200705-664OC Döring, 2004, Early intervention and prevention of lung disease in CF: a European consensus, J Cyst Fibros., 3, 67, 10.1016/j.jcf.2004.03.008 Waters, 2015, Cystic fibrosis microbiology: Advances in antimicrobial therapy, J Cyst Fibros., 14, 551, 10.1016/j.jcf.2015.02.005 Konstan, 2011, Safety, efficacy and convenience of tobramycin inhalation powder (TIP™) in CF patients, The EAGER trial. J Cystic Fib., 10, 54, 10.1016/j.jcf.2010.10.003 Knudsen, 2009, Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centers in Denmark, Norway and Sweden, J Cystic Fib., 8, 135, 10.1016/j.jcf.2008.11.001 Treggiari, 2011, Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis, Arch Pediatr Adolesc Med;1;, 165, 847, 10.1001/archpediatrics.2011.136 Ratjen, 2010, Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial, Thorax., 65, 286, 10.1136/thx.2009.121657 Mogayzel, 2014, Cystic Fibrosis Foundation Pulmonary Clinical Practice. Guidelines committee cystic fibrosis foundation pulmonary guideline* ‐ pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection, Ann Am Thorac Soc., 11, 1640, 10.1513/AnnalsATS.201404-166OC Mogayzel, 2013, Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health, Am J Respir Crit Care Med., 187, 680, 10.1164/rccm.201207-1160OE Wainwright, 2015, Lumacaftor‐Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, N Engl J Med., 373, 220, 10.1056/NEJMoa1409547 Cunha, 2003, Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns, J Pediatr (RioJ)., 79, 550 Cunha, 2005, Risk factors for bronchopulmonary dysplasia in very low birth weight newborns treated with mechanical ventilation in the first week of life, J Trop Pediatr., 51, 334, 10.1093/tropej/fmi051 Sanchez-Solis, 2012, Lung function among infants born preterm, with or without bronchopulmonary dysplasia, Pediatr Pulmonol., 47, 674, 10.1002/ppul.21609 Palta, 2001, Respiratory symptoms at age 8 years in a cohort of very low birth weight children, Am J Epidemiol., 154, 521, 10.1093/aje/154.6.521 Fawke, 2010, Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study, Am J Respir Crit Care Med., 182, 237, 10.1164/rccm.200912-1806OC Broström, 2013, Obstructive pulmonary disease in old age among individuals born preterm, Eur J Epidemiol., 28, 79, 10.1007/s10654-013-9761-7 Kotecha, 2013, Effect of preterm birth on later FEV1: a systematic review and meta‐analysis, Thorax., 68, 760, 10.1136/thoraxjnl-2012-203079 Gough, 2014, Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia, Eur Respir J., 43, 808, 10.1183/09031936.00039513 Iyengar, 2015, Drug therapy for the prevention and treatment of associated pulmonary hypertension: a retrospective study of efficacy and safety, Eur J Pediatr., 6, 1 Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Review. Front Pharmacol. 2015;16;6:12. Tan, 2015, Sildenafil therapy in bronchopulmonary dysplasia‐associated pulmonary hypertension: a retrospective study of efficacy and safety, Eur J Pediatr., 174, 1109, 10.1007/s00431-015-2515-7 Brower, 2014, The etiologies of non‐CF bronchiectasis in childhood: a systematic review of 989 subjects, BMC Pediatrics., 14, 1, 10.1186/s12887-014-0299-y Chang, 2003, Non‐CF bronchiectasis: clinical and HRCT evaluation, Pediatr Pulmonol, 35, 477, 10.1002/ppul.10289 Yap, 2015, New therapeutic options for noncystic fibrosis bronchiectasis, Curr Opin Infect Dis, 28, 171, 10.1097/QCO.0000000000000147 Wong, 2012, Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial, Lancet., 380, 660, 10.1016/S0140-6736(12)60953-2 Madsen, 2005, Plastic bronchitis: new insights and a classification scheme, Paediatr Respir Rev., 6, 292, 10.1016/j.prrv.2005.09.001